Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Colorectal cancer

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Large-bowel obstruction, perforation, uncontrolled bleeding or sepsis in a patient with possible colorectal cancer requires simultaneous resuscitation, urgent CT and senior colorectal review. Do not delay emergency source control while pursuing routine outpatient confirmation.

Synopsis

Recognise colorectal cancer across symptomatic, screening and emergency presentations, investigate without false reassurance, and coordinate stage-specific multidisciplinary treatment and surveillance safely.

  • Right-sided cancers often present with iron-deficiency anaemia, fatigue, weight loss or a mass; left-sided lesions more often produce altered bowel habit, bleeding or obstruction.
  • Rectal cancer may cause bright bleeding, tenesmus, urgency, incomplete evacuation or a palpable lesion on digital rectal examination.
  • In symptomatic adults, quantitative FIT supports referral decisions, but a rectal or abdominal mass, obstruction, persistent unexplained symptoms or strong clinical concern must override a reassuring result.
  • The symptomatic NICE referral threshold and the NHS bowel-screening threshold serve different populations and must never be interchanged; screening policy also varies between UK nations.
  • Colonoscopy with biopsy usually establishes diagnosis; CT colonography is an alternative when colonoscopy is unsuitable or incomplete but cannot provide tissue.
  • Stage with CT chest, abdomen and pelvis; add high-resolution pelvic MRI for rectal cancer and discuss every confirmed case at a specialist colorectal MDT.
  • Test colorectal tumours for mismatch-repair deficiency or microsatellite instability because results affect Lynch syndrome assessment, prognosis and selected systemic treatment.
  • CEA is useful as a baseline and for selected follow-up, but a normal value neither excludes cancer nor makes surveillance imaging unnecessary.

Key red flags

Rectal lesion

Tenesmus, urgency, mucus, bleeding and a sense of incomplete evacuation should prompt inspection and digital rectal examination where appropriate, with urgent referral even if FIT is low when a mass is felt.

Obstructing or perforated tumour

Absolute constipation, vomiting, marked distension, peritonism, fever, shock or free air indicate an oncological surgical emergency; closed-loop caecal dilatation can perforate remotely from a distal tumour.

Metastatic or systemic disease

Hepatomegaly, jaundice, ascites, respiratory symptoms, bone pain, cachexia or venous thromboembolism may be the first clue to advanced disease and require prompt staging rather than symptom-only treatment.

Investigation priorities

01
Quantitative faecal immunochemical testFirst step

Triage eligible symptomatic people into the colorectal cancer pathway.

Management branches

ReferralSymptomatic suspected-cancer route

New colorectal symptoms, unexplained iron deficiency, or a concerning examination finding.

  1. Take a site-focused history, examine the abdomen, inspect the anus where relevant and perform digital rectal examination for rectal symptoms when clinically appropriate.
  2. Request quantitative FIT according to the current symptomatic pathway, plus blood count and iron studies, without allowing testing logistics to delay referral for a mass, obstruction or marked concern.
  3. Refer on the applicable suspected-cancer pathway when criteria are met; document what happens after a low result and arrange active review if symptoms persist or evolve.
  4. Use colonoscopy with biopsy or CT colonography as selected by the diagnostic service, then stage confirmed cancer and present it to the colorectal MDT.

Key medicines

Intravenous broad-spectrum antimicrobialsUse the local emergency intra-abdominal sepsis regimen with renal adjustment and early review.Take cultures where feasible without delaying therapy, check allergy and organ function, obtain source control urgently, and narrow or stop treatment with microbiology advice.
Fluoropyrimidine-based systemic therapyRegimen, cycle timing and dose are calculated by the specialist oncology protocol.Dihydropyrimidine dehydrogenase assessment, performance status, renal function, interactions and toxicity plans are essential; mucositis, diarrhoea, cytopenia and cardiotoxicity require prompt oncology contact.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG151 colorectal cancer recommendationsDiagnosis, staging, molecular testing, treatment and follow-up.
  • NICE NG12 suspected cancer referralsSymptom and FIT-based referral recommendations.
  • ACPGBI and BSG symptomatic FIT guidelineSpecialty guidance for FIT in symptomatic patients.
  • NHS bowel cancer screening pathway specificationEngland programme pathway; devolved programmes differ.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom